Patients and Caregivers
Denali is committed to partnering with patients to discover and develop new, effective therapies for neurodegenerative diseases.
Before a new therapy can be made available to the general public, multiple studies involving healthy volunteers and patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Currently, Denali is conducting the following clinical trials:
- Study to Evaluate DNL201 in Subjects with Parkinson’s Disease
- Study to Evaluate DNL747 in Subjects with Alzheimer's Disease
- Study to Evaluate DNL747 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
- Study to Evaluate DNL151 in Subjects with Parkinson's Disease
- Study of Potential Treatment-Responsive Biomarkers in Hunter Syndrome
To learn more about the above studies please visit ClinicalTrials.gov
If you are interested in receiving updates from Denali about our clinical trials and research, please provide your information below.
AREAS OF INTEREST
Select all that apply to you.
* Required information
If you would like to opt-out of receiving Denali updates from us, please contact us.
POLICY ON EXPANDED ACCESS TO INVESTIGATIONAL DRUGS
Denali understands that there are some cases when a patient is unable to participate in a clinical trial, and other treatment options have been exhausted. In those cases, the patient's physician may choose to request access to an investigational drug outside of a clinical trial via what is termed Expanded Access in the United States.
Currently, participation in clinical trials is the only way for patients to gain access to Denali's investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.